Jim Simons Capricor Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 53,150 shares of CAPR stock, worth $246,615. This represents 0.0% of its overall portfolio holdings.

Number of Shares

53,150

Previous 146,321 63.68%

Holding current value

$246,615

Previous $716,000 49.58%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$3.61 - $6.88 $336,347 - $641,016	-93,171 Reduced 63.68%	53,150 $361,000
Q4 2023 Feb 13, 2024	BUY	$2.71 - $5.08 $281,027 - $526,796	103,700 Added 243.31%	146,321 $716,000
Q3 2023 Nov 14, 2023	SELL	$3.42 - $7.85 $12,996 - $29,830	-3,800 Reduced 8.19%	42,621 $146,000
Q2 2023 Aug 11, 2023	BUY	$3.76 - $5.05 $59,784 - $80,295	15,900 Added 52.1%	46,421 $222,000
Q1 2023 May 12, 2023	BUY	$3.78 - $5.03 $28,350 - $37,725	7,500 Added 32.58%	30,521 $129,000

Q4 2022 Feb 13, 2023	BUY	$3.36 - $4.97 $43,078 - $63,720	12,821 Added 125.7%	23,021 $89,000
Q3 2022 Nov 14, 2022	BUY	$3.61 - $6.08 $36,822 - $62,016	10,200 New	10,200 $61,000
Q3 2020 Nov 13, 2020	SELL	$4.08 - $9.81 $811,104 - $1.95 Million	-198,800 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$1.0 - $8.5 $95,185 - $809,072	95,185 Added 91.86%	198,800 $914,000
Q1 2020 May 14, 2020	BUY	$0.94 - $2.02 $18,640 - $40,056	19,830 Added 23.67%	103,615 $124,000
Q4 2019 Feb 13, 2020	BUY	$1.04 - $3.55 $45,002 - $153,615	43,272 Added 106.81%	83,785 $107,000
Q3 2019 Nov 13, 2019	BUY	$2.38 - $6.23 $96,420 - $252,395	40,513 New	40,513 $150,000

Others Institutions Holding CAPR

# of Institutions

Shares Held

4.74M

Call Options Held

123K

Put Options Held

53.8K

View Full List

About CAPRICOR THERAPEUTICS, INC.

Ticker CAPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,346,200
Market Cap $113M
Description
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...

More about CAPR

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account